Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 17/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9222958 | 1.00 | SRD5A2 (0.49) | SRD5A2HSD17B1CYP19A1 | |
| SCHEMBL6841928 | 0.91 | SRD5A2 (0.47) | SRD5A2HSD17B1CYP19A1 | |
| SCHEMBL6841929 | 0.91 | SRD5A2 (0.47) | SRD5A2HSD17B1CYP19A1 | |
| SCHEMBL9226232 | 0.84 | SRD5A2 (0.68) | SRD5A2CYP19A1 | |
| SCHEMBL9226234 | 0.84 | SRD5A2 (0.68) | SRD5A2CYP19A1 | |
| SCHEMBL16389403 | 0.83 | SRD5A2 (0.39) | SRD5A2CYP19A1 | |
| SCHEMBL4102408 | 0.83 | SRD5A2 (0.39) | SRD5A2CYP19A1 | |
| SCHEMBL17634422 | 0.83 | SRD5A2 (0.39) | SRD5A2CYP19A1 | |
| SCHEMBL15079262 | 0.83 | SRD5A2 (0.39) | SRD5A2CYP19A1 | |
| SCHEMBL2320541 | 0.81 | SRD5A2 (0.36) | SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997023498-A1 | 18-METHYL 16-METHYLENE 19-NOR PREGNANE DERIVATIVES AS PROGESTINS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION THEREOF | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1997-07-03 | — | — | WO | claimed |
| EP-2178899-B1 | 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2010066354-A1 | USE OF 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
| EP-2178899-A1 | 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-20090048218-A1 | 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008151745-A1 | 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-1997023498-A1 | 18-METHYL 16-METHYLENE 19-NOR PREGNANE DERIVATIVES AS PROGESTINS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION THEREOF | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1997-07-03 | — | — | WO | disclosed |
| US-5438134-A | Endocrine disorders, reproductive control | JENAPHARM GMBH (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0538348-A1 | PROCESS FOR PRODUCING UNSATURATED 17-ALPHA-CYANOMETHYL-17-BETA-HYDROXYSTEROIDS. | JENAPHARM GMBH (DE) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000991-A1 | PROCESS FOR PRODUCING UNSATURATED 17-ALPHA-CYANOMETHYL-17-BETA-HYDROXYSTEROIDS | JENAPHARM GMBH (DE) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048218-A1 | 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B7, HSD17B11, CYP17A1 | SRD5A2 14/4885HSD17B1 6/4885CYP19A1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.